Services
Induced pluripotent stem cell (iPSC) services
Services currently available in the core include:
- Skin punch biopsy and fibroblast isolation, expansion and cryopreservation.
- Peripheral blood mononuclear cell isolation from whole blood and cryopreservation.
- iPSC reprogramming via CytoTune 2.0.
- iPSC pluripotency and trilineage assessment.
- iPSC clone expansion.
- Karyotyping and DNA fingerprinting (SIDV) of iPSC lines.
- iPSC regulatory support.
Tissue-derived stem cell services
By the third quarter of 2025, the core also will offer:
- Surgical residual and biopsy tissue collection.
- Adult stem cell isolation.
- Expansion to 2D and 3D tissue-specific organoid cultures.
- Mycoplasma testing.
- Cryopreservation and delivery of quality control-validated organoids to the principal investigator.
The Stem Cell and Organoid Core plans to develop additional service lines by the end of 2025 that will greatly expand support for organoid and microphysiological systems development. This includes the production of iPSC-derived differentiated cells, such as neurons, astrocytes and hepatocytes, and the production of iPSC-derived organoids and organoid-on-chip platforms. Future services also will include pass-through to the human gene editing core.